The global anaplastic thyroid cancer drug market is expected to grow at a CAGR of nearly 6% during the forecast period. (2022-2028). Anaplastic thyroid carcinoma is a kind of thyroid cancer that is rare and aggressive. Thyroid cancer accounts for roughly 1-2 percent of all cancers. In May 2018, the combination of tafinlar and mekinist has been approved for the treatment of BRAF V600E mutation-positive ATC that cannot be surgically treated or has spread to other organs. Melanoma and non-small cell lung cancer are two more BRAF V600 mutation-positive metastatic cancers for which Tafinlar and Mekinist have been licensed. This was the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and it's the third cancer with this specific gene mutation that this drug combination has been approved to treat. This approval illustrates that targeting the same molecular pathway in a variety of disorders is an effective method to speed up the development of therapies that could benefit a larger number of people.
Browse the full report description “Global Anaplastic Thyroid Cancer Drug Market Size, Share & Trends Analysis Report by Product (Sorafenib, Paclitaxel and Pazopanib HCL, MLN0128, Everolimus, CA4 P, Bevacizumab and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/anaplastic-thyroid-cancer-drug-market
Further, the increasing awareness amongst the population for thyroid cancer, rising medical infrastructure facilities, and innovative technological advancements is contributing to the growth of the market. The number of drugs and formulations are under pipeline information and expected to enter the anaplastic thyroid cancer drug market during the forecast period. The major pipeline drugs are bevacizumab, sorafenib, everolimus, and so on. In addition, the low prevalence of the disease is a restraining factor hampering the growth of the market followed by the rising cost of research & developments, diagnosis, and treatment.
Besides, the rising prevalence of thyroid cancer is further propelling the growth of the market. For Instance, according to the American Society of Clinical Oncology in 2021, an estimated 44,280 adults including 12,150 men and 32,130 women were diagnosed with thyroid cancer in the US with an estimated mortality rate of 2,200 mortalities including 1,050 men and 1,150 women from this disease.
Market Coverage
Segment Covered-
By Product
Regions Covered-
Competitive Landscape- including Novartis International AG. Pfizer Inc., Daiichi Sankyo Co. Ltd., and others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Anaplastic Thyroid Cancer Drug Market Report Segment
By Product
Global Anaplastic Thyroid Cancer Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/anaplastic-thyroid-cancer-drug-market